I think that what a lot of people dont realise yet is that...

I think that what a lot of people dont realise yet is that carfilzomib is very early in its life having not been on the market that long and it is regarded by many physicians to be a future front line drug in the treatment of myeloma. If pat sm6 and carfilzomib work together well pat sm6 could become part of the frontline attack on myeloma within a very short space of time. It is quite possible to progress very quickly to market from here and not only just be a bit player but be the first choice for patients and the upside from here for patrys is huge imo